© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
Gene L. Colice, MDDirector, Pulmonary, Critical Care, and Respiratory Services
Washington Hospital CenterProfessor of Medicine
George Washington University
Improving Asthma Care: An Update for Managed CareEmerging Therapeutic Options
for Asthma
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
2
Presenter:Gene L. Colice, MDDirector, Pulmonary, Critical Care, and Respiratory ServicesWashington Hospital CenterProfessor of MedicineGeorge Washington UniversityWashington, DC
Moderator:Jeff Prescott, PharmD, RPhDirector of Scientific ContentThe American Journal of Managed Care
This activity is supported by an educational grant from Merck & Co, Inc.
Faculty InformationFaculty Information
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
3
Educational ObjectivesEducational ObjectivesAfter completing this activity, the participant should be able to:
Discuss the demographics, economics, and pathophysiology of asthmaDescribe the significance of unmet needs among people with asthma Examine new and emerging therapies for asthma and assess their role in the treatment of asthmaIdentify strategies for improving asthma control
The contents of this CE activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
4
DisclosuresDisclosuresAccording to the disclosure policies of the University of Cincinnati and Pharmacy Times Office of Continuing Professional Education, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the University of Cincinnati and Pharmacy Times Office of Continuing Professional Education to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
Gene L. Colice, MD reports consultancy, advisory board, and speaker’s bureau assignments from Abbott, Boehringer Ingelheim, Genentech, GlaxoSmithKline, MedImmune, Pearl Therapeutics, Pfizer, and Teva.
The planning staff from the University of Cincinnati, The American Journal of Managed Care, and the Pharmacy Times Office of Continuing Professional Education have no relevant financial relationships to disclose.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
5
Accreditation StatementThis activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the University of Cincinnati. The University of Cincinnati is accredited by theACCME to provide continuing medical education for physicians.
Credit DesignationThe University of Cincinnati designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extentof their participation in the activity.
Physician AccreditationPhysician Accreditation
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
6
Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1 contact hour (0.1 CEU) under the ACPE universal program number 0290-9999-11-018-H01-P. This program is available for CE credit through April 19, 2012.
Type of Activity: Knowledge-based.
Pharmacy AccreditationPharmacy Accreditation
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
Emerging Therapeutic Options for Asthma
Send discussion questions to [email protected]
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
8Send discussion questions to [email protected]
What is the current state of asthma care?
How can we improve asthma care?
What are the new therapeutic options for asthma care and how effective are they?
Emerging Therapeutic Options for AsthmaEmerging Therapeutic Options for Asthma
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
9Send discussion questions to [email protected]
Approximately 23.3 million Americans (2008 data)Affects all age groups◦ <5 yrs 1.28 million◦ 5-17 yrs 5.68 million◦ 18-44 yrs 7.94 million◦ 45-64 yrs 5.77 million◦ >65 yrs 2.65 million
American Lung Association. Trends in asthma morbidity and mortality: February 2010. http://www.lungusa.org.
Asthma DemographicsAsthma Demographics
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
10Send discussion questions to [email protected]
Asthma DemographicsAsthma Demographics
American Lung Association. Trends in asthma morbidity and mortality: February 2010. http://www.lungusa.org.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
11Send discussion questions to [email protected]
Akinbami LJ, et al. Asthma prevalence, health care use, and mortality: United States, 2005-2009. National health statistics reports; No. 32. Hyattsville, MD: National Center for Health Statistics; 2011.
Utilization and Mortality from Asthma Utilization and Mortality from Asthma is Disparate (2005is Disparate (2005--2007)2007)
A rate ratio of 1.0 (dashed line) indicates equal rates between the groups being compared.
<18 years vs ≥18 years
Femalevs Male
Othervs White
Blackvs White
0.14
1.93
0.79
1.29
1.23
2.22
0.89
1.08
1.52
3.32
0.73
0.96
1.77
0.98
0.68
0.82
0 1 2 3 4
Total ambulatory visitEmergency department visitHospitalizationDeath
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
12Send discussion questions to [email protected]
American Lung Association. Asthma in adults fact sheet. February 2010. CDC Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2008. Series 10, Number 242; December 2009. CDC Summary Health Statistics for U.S. Children: National Health Interview Survey, 2008. Series 10, Number
244; December 2009. Akinbami LJ, et al. National health statistics reports; No. 32. Hyattsville, MD: National Center for Health Statistics; January 2011.
11--year Trends in Asthma, Utilization, year Trends in Asthma, Utilization, and Mortalityand Mortality
12.8 million with an attack
24.6 million with asthma
2009 Trend2008
12.7 million with an attack
23.4 million with asthma
3447 asthma deaths3613 asthma deaths
456,000 hospitalizations444,000 hospitalizations
1.75 million ED visits1.7 million ED visits
Trend20072006
ED = emergency department.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
13Send discussion questions to [email protected]
Asthma in America Survey, 1998:◦ 2 of 5 (39%) people with moderate persistent
asthma and >2 of 3 (68%) with severe persistent asthma did NOT consider their asthma to be “well controlled” or “completely controlled”
Asthma Insight and Management Survey, 2009: ◦ 42% of asthma patients were “poorly” or “not well
controlled”
Asthma in America™: A Landmark Survey. Executive Summary. SRBI, 2004.Murphy K et al. Ann Asthma Immunol. 2010;105(suppl 5):A50. Abstract P86.
Has the State of Asthma Care Changed Has the State of Asthma Care Changed in the Last 10 Years?in the Last 10 Years?
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
14Send discussion questions to [email protected]
Direct medical costs◦ $5.5 billion – hospital care ◦ $5.9 billion – prescription care ◦ $4.2 billion – physicians’ services
Indirect medical costs◦ $3.1 billion – morbidity◦ $2.0 billion – mortality
Asthma EconomicsAsthma Economics
American Lung Association. Trends in asthma morbidity and mortality: February 2010. http://www.lungusa.org.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
15Send discussion questions to [email protected]
Mauad T et al. Abnormal Alveolar Attachments with Decreased Elastic Fiber Content in Distal Lung in Fatal Asthma. Am J Respir Crit Care Med. 2004;170(8):857-862.
Airway Inflammation in AsthmaAirway Inflammation in AsthmaSmall airway of acontrol subject
Small airway of asubject with fatal asthma
Airway inflammation is the underlying reason for asthma symptoms, airflow obstruction, exacerbations, and airway hyperresponsiveness.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
16Send discussion questions to [email protected]
Asthma Asthma PathophysiologyPathophysiology
National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
17Send discussion questions to [email protected]
Asthma Asthma PathophysiologyPathophysiology
National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
18Send discussion questions to [email protected]
Assessment of asthma should include:◦ Severity: the intrinsic intensity of the disease process ◦ Control: the degree to which the manifestations of asthma are
minimized and the goals of therapy are met◦ Responsiveness: the ease with which asthma control is achieved
by therapyAssessment of severity and control should include:◦ Impairment: frequency and intensity of symptoms and functional
limitations the patient is experiencing◦ Risk: the likelihood of either asthma exacerbations, progressive
decline in lung function (or, for children, reduced lung growth), or risk of adverse effects from medication
Expert Panel Report 3 (EPR3) Recommended Expert Panel Report 3 (EPR3) Recommended Approach to Asthma EvaluationApproach to Asthma Evaluation
National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel Report 3: guidelines for the diagnosis and management of asthma. Full report 2007.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
19Send discussion questions to [email protected]
Assessing Severity Prior to Initiating Assessing Severity Prior to Initiating Controller MedicationController Medication
AssessingInitial
AsthmaSeverity
Impairment
Risk
Nighttime awakeningsShort-acting beta2-agonist (SABA) useSchool/work days missedInterference with normal activityQuality of lifeLung function (spirometry)
Previous oralcorticosteroid useFrequency and severity of recent symptoms indicative of persistent diseaseUrgent care visits
National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
20Send discussion questions to [email protected]
Classifying Asthma Severity in Patients Not Taking Classifying Asthma Severity in Patients Not Taking LongLong--term Controller Medication (Children 5term Controller Medication (Children 5--11 Years)11 Years)
EIB = exercise-induced bronchospasm; FVC = forced vital capacity.
Impairment
Symptoms
Nighttime awakenings
SABA use for symptom control (not prevention of EIB)
Interference with normal activity
Lung function
≤2 days/week >2 days/weekbut not daily Daily Throughout the
day
≤2x/month 3-4x/month >1x/week but not nightly
Often7x/week
≤2 days/week >2 days/weekbut not daily Daily Several times
per day
None Minor limitation Some limitation Extremely limited
Normal FEV1between exacerbationsFEV1 >80% predictedFEV1/FVC >85%
FEV1 ≥80% predicted
FEV1/FVC >80%
FEV1=60%-80% predicted
FEV1/FVC=75%-80%
FEV1 <60% predicted
FEV1/FVC <75%
RiskExacerbations requiring oral systemic corticosteroids
0-1/year ≥2/year
Consider severity and interval since last exacerbation. Frequency and severity may fluctuate over time for patients in any severity
category. Relative annual risk of exacerbations may be related to FEV1.
Components of SeverityIntermittent
(step 1)
PersistentMild
(step 2)Moderate(step 3)
Severe(step 3 or 4)
National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
21Send discussion questions to [email protected]
Asthma Treatment and ControlAsthma Treatment and Control
National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
22Send discussion questions to [email protected]
Once therapy has begun, the emphasis is on the assessment of asthma control
The level of asthma control will guide decisions either to maintain or adjust therapy
Asthma Treatment and ControlAsthma Treatment and Control
National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
23Send discussion questions to [email protected]
Assessing Control After Initiating Assessing Control After Initiating Controller MedicationController Medication
AssessingAsthmaControl
Impairment
Risk
Fewer daily symptomsFewer nighttime awakeningsLess frequent SABA useMaintain activity levelMaintain lung function
Not preventing exacerbationsand urgent care visitsPersistent airflow obstructionMedication-related adverse eventsNot providing optimal treatmentNot preventing lung function decline
National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
24Send discussion questions to [email protected]
Case Study #2: 32Case Study #2: 32--yearyear--old Male,old Male,Asthma Control Test (ACT) ScoreAsthma Control Test (ACT) Score
Scoring: ≤15 = poorly controlled; 16-19 = not well controlled, ≥20 = well controlled
Completely controlled
Well controlled
Somewhat controlled
Poorly controlled
Not controlled at all
5. How would you rate your asthma control during the past 4 weeks?
Not at allOnce a week or less
2 or 3 times per week
1 or 2 times per day
3 or more times per day
4. During the past 4 weeks, how often have you used your rescue inhaler or nebulizer medication (such as albuterol)?
Not at allOnce or twiceOnce a week2 or 3 nights
a week4 or more
nights a week
3. During the past 4 weeks, how often did your asthma symptoms (wheezing, coughing, shortness of breath, chest tightness, or pain) wake you up at night, or earlier than usual in the morning?
Not at allOnce or twice a week
3 to 6 times a weekOnce a dayMore than once
a day
2. During the past 4 weeks, how often have you had shortness of breath?
None of the time
A little of the time
Some of the time
Most of thetime
All of the time
1. In the past 4 weeks, how much of the time did your asthma keep you from getting as much done at work, at school, or at home? Score
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
5
4
5
4
4
22Score
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
25Send discussion questions to [email protected]
Assessing Asthma Control in Individuals Assessing Asthma Control in Individuals ≥≥12 Years of Age12 Years of Age
Components of Control Well Controlled Not Well Controlled Very Poorly Controlled
Impairment
Symptoms ≤2 days/week >2 days/week Throughout the day
Nighttime awakenings ≤2x/month 1-3x/week ≥4x/week
SABA use for symptom control (not prevention of EIB)
≤2 days/week >2 days/week Several times per day
Interference with normal activity None Some limitation Extremely limited
FEV1 or peak flow >80% predicted/personal best
60%-80% predicted/personal best
<60% predicted/personal best
Validated questionnairesATAQACQACT
0≤0.75≥20
1-2≥1.5
16-19
3-4N/A≤15
Risk
Exacerbations requiring oral systemic corticosteroids
0-1 per year ≥2 per year
Consider severity and interval since last exacerbation.
Progressive loss of lung function Evaluation requires long-term follow-up care.
Treatment-related adverse effects
Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in overall assessment of risk.
National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
26Send discussion questions to [email protected]
Stepwise Approach for Managing Asthma Stepwise Approach for Managing Asthma in Individuals in Individuals ≥≥12 Years Old12 Years Old
IntermittentAsthma
Persistent Asthma: Daily MedicationConsult with asthma specialist if step 4 care or higher is required.
Consider consultation at step 3.
STEP 1
PREFERRED
SABA prn
STEP 2
PREFERRED
Low-dose ICS
Alternative:Cromolyn,
LTRA, nedocromil, or theophylline
STEP 3
PREFERRED
Low-dose ICS+ LABA
ORMedium-dose
ICS
Alternative:Low-dose ICS
+ LTRA, theophylline, or zileuton
Quick-relief medication for all patients:• SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms: up to 3 treatments at 20-
minute intervals as needed. Short course of systemic oral corticosteroids may be needed.• Use of SABA >2 days/week for symptom relief indicates inadequate control and the need to step up treatment.
STEP 4
PREFERRED
Medium-dose ICS + LABA
Alternative:Medium-dose ICS + LTRA, theophylline, or zileuton
STEP 5
PREFERRED
High-dose ICS + LABA
AND
Consider omalizumabfor patients who have allergies
STEP 6
PREFERRED
High-dose ICS + LABA + oral
systemic corticosteroid
AND
Consider omalizumab for
patients who have allergies
Each step: Patient education, environmental control, and management of comorbidities.Steps 2-4: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma.
Step up if needed(first, check adherence,
environmental control, and comorbid
conditions)
Step down if possible
(and asthma is well controlled at least 3 months)
ASSESS CONTROL
National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
27Send discussion questions to [email protected]
The goal of treatment is to achieve asthma control
Unfortunately, not all patients achieve that goal
Asthma Treatment and Control?Asthma Treatment and Control?
National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
28Send discussion questions to [email protected]
Bateman ED, Boushey HA, Bousquet J, et al. Can guidelines-defined asthma control be achieved? the gaining optimal asthma control study. Am J Respir Crit Care Med. 2004;170(8):836-844.
Asthma Treatment and Control?Asthma Treatment and Control?
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
29Send discussion questions to [email protected]
“Asthma is an inflammatory disorder of the airways that affects approximately 300 million people worldwide. A significant number of these patients, estimated at 10% to 15%, have severe disease that is mechanistically heterogeneous and poorly controlled by conventional therapy.”
Bhat KD, Calhoun WJ. Omalizumab in asthma: is the therapeutic window too small? Chest. 2011;139(1):8-10.
Asthma Treatment and Control?Asthma Treatment and Control?
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
30Send discussion questions to [email protected]
Novel ICS combinationsCytokine inhibitorsPDE inhibitorsOligonucleotidesNon-pharmacologic options
Emerging Treatment OptionsEmerging Treatment Options
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
31Send discussion questions to [email protected]
ICS plus leukotriene receptor antagonist (LTRA)ICS plus anticholinergicICS plus omalizumab
Novel ICS CombinationsNovel ICS Combinations
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
32Send discussion questions to [email protected]
MONICA studyAdult patients (n = 1681) with mild to moderate asthma Montelukast 10 mg added to ICS or ICS + LABAFollowed for 6 months in a prospective, open-label observational study Primary end point: change in ACT score Secondary end points: mini-AQLQ and FEV1/PEF
Virchow JC, Mehta A, Ljungblad L, Mitfessel H; MONICA study group. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast In Chronic Asthma (MONICA) study. Respir Med. 2010;104(5):644-651.
ICS Plus LTRAICS Plus LTRA
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
33Send discussion questions to [email protected]
ICS Plus LTRAICS Plus LTRA
Virchow JC, Mehta A, Ljungblad L, Mitfessel H; MONICA study group. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast In Chronic Asthma (MONICA) study. Respir Med. 2010;104(5):644-651.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
34Send discussion questions to [email protected]
Omalizumab is recommended for patients with severe uncontrolled asthma on ICS or ICS plus LABA (step 5 or 6)
ICS Plus ICS Plus OmalizumabOmalizumab
National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
35Send discussion questions to [email protected]
Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.
ICS Plus ICS Plus OmalizumabOmalizumab
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
36Send discussion questions to [email protected]
Rodrigo FJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systemic review. Chest. 2011;139(1):28-35.
Rodrigo et al (2011) analyzed data from 8 RCTs and concluded that the addition of omalizumab◦ Reduced
Asthma exacerbations (37 exacerbations / 100 patient yrs vs69.9 exacerbations / 100 patient yrs – placebo) (primary outcome)Rescue medication use (secondary outcome)Asthma symptom scores (secondary outcome)
◦ IncreasedPercentage of patients able to stop their corticosteroid use completely (41.8% vs 21% – placebo) (primary outcome)Pulmonary function (FEV1 or PEF) (secondary outcome)Morning PEF (secondary outcome)Quality of life (AQLQ) scores (secondary outcome)
ICS Plus ICS Plus OmalizumabOmalizumab
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
37Send discussion questions to [email protected]
TALC study (Tiotropium Alternative to Low dose Corticosteroid study)Tiotropium approved for COPD, not asthmaAdult patients (n = 210) with poorly controlled asthma on ICSThree-way, double-blind, triple-dummy crossover trial1. Doubling dose of ICS (beclomethasone 160 μg twice daily),2. Normal dose ICS (beclomethasone 80 μg twice daily) plus the LABA
salmeterol xinafoate (50 μg twice daily), or 3. Normal dose ICS (beclomethasone 80 μg twice daily) plus tiotropium
bromide (18 μg each morning)
Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363(18):1715-1726.
ICS Plus ICS Plus AnticholinergicAnticholinergic
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
38Send discussion questions to [email protected]
Primary end point – morning PEFSecondary end points – evening PEF, FEV1, various asthma and QoL scores
ICS Plus ICS Plus AnticholinergicAnticholinergic
Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363(18):1715-1726.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
39Send discussion questions to [email protected]
Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363(18):1715-1726.
ICS Plus ICS Plus AnticholinergicAnticholinergic
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
40Send discussion questions to [email protected]
Long AA. Monoclonal antibodies and other biologic agents in the treatment of asthma. MAbs. 2009;1(3):237-246.
Numerous targetedstrategies studied. The most promising are:• IL-5 antagonist
(mepolizumab)• IL-2α receptor antagonist
(daclizumab)• TNF antagonists
(etanercept, infliximab)
Cytokine InhibitorsCytokine Inhibitors
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
41Send discussion questions to [email protected]
Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumabin patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176(11):1062-1071.
Mepolizumab◦ A humanized monoclonal antibody against interleukin-5◦ IL-5 is believed to be a key cytokine in eosinophil
differentiation, recruitment, activation, and survival at sites of allergic inflammation◦ Initial RCTs were not positive (eg, Flood-Page et al 2007)◦ Recent studies focusing on patients with eosinophilic
asthma show promise
Cytokine Inhibitors: Cytokine Inhibitors: MepolizumabMepolizumab
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
42Send discussion questions to [email protected]
Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New Engl J Med. 2009;360(10):973-984.
Haldar et al (2009) performed a randomized, double-blind, placebo-controlled, parallel-group study of patients (n = 61) with refractory eosinophilic asthma and a history of recurrent severe exacerbations Patients received 12 monthly infusions of mepolizumab(750 mg; n = 29) or placebo (n = 32) At the end of the 50-week study, the patients treated with mepolizumab had ◦ Fewer severe exacerbations (2.0 vs 3.4 mean exacerbations per
patient; relative risk, 0.57; 95% CICI, 0.32 to 0.92; P = .02)◦ Higher increase in AQLQ (mean increase from baseline, 0.55 vs
0.19; mean difference between groups, 0.35; 95% CI, 0.08 to 0.62; P = .02)
Cytokine Inhibitors: Cytokine Inhibitors: MepolizumabMepolizumab
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
43Send discussion questions to [email protected]
Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med. 2008;178(10):1002-1008.
Daclizumab◦ A monoclonal antibody that binds to the receptor for IL-2
and inhibits the biological activity of IL-2◦ Busse et al (2008) performed a randomized, double-
blinded, placebo-controlled study in adults with moderate-to-severe persistent asthma given daclizumab (intravenous loading dose, 2 mg/kg, then 1 mg/kg; n = 88) or placebo (n = 27) every 2 weeks while also being tapered off of an ICS
Cytokine Inhibitors: Cytokine Inhibitors: DaclizumabDaclizumab
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
44Send discussion questions to [email protected]
Cytokine Inhibitors: Cytokine Inhibitors: DaclizumabDaclizumab
Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med. 2008;178(10):1002-1008.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
45Send discussion questions to [email protected]
During the first 12 weeks of the study, ◦ Daclizumab improved FEV1 (daclizumab, 4.4 % vs
placebo, 1.5 %; P = .05), and reduced daytime asthma symptoms (P = .018) and short-acting inhaled beta2-agonist use (P = .009)◦ Daclizumab treatment prolonged time to exacerbation
(P = .024)During the final 24 weeks of study,◦ Significant differences in outcomes were not observed
between the 2 groups once the ICS dose was tapered off
Cytokine Inhibitors: Cytokine Inhibitors: DaclizumabDaclizumab
Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med. 2008;178(10):1002-1008.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
46Send discussion questions to [email protected]
Medications that can interfere with tumor necrosis factor (TNF) have also been investigated. Among them, the TNF antagonist etanercept shows some promise Two clinical studies have examined the efficacy of etanercept in patients with asthma
Cytokine Inhibitors: Cytokine Inhibitors: EtanerceptEtanercept
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
47Send discussion questions to [email protected]
Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006;354(7):697-708.
Berry et al (2006) conducted a small crossover study (n = 10) in patients with mild-to-moderate refractory asthmaPatients given etanercept (25 mg twice weekly for 10 weeks) had: ◦ Significant increase in the concentration of
methacholine required for 20% decrease in FEV1◦ Increase in post-bronchodilator FEV1◦ Higher AQLQ scores
Cytokine Inhibitors: Cytokine Inhibitors: EtanerceptEtanercept
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
48Send discussion questions to [email protected]
Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax. 2008;63(7):584-591.
Morjaria et al (2008) conducted a randomized, double blind, placebo-controlled, parallel group trial Etanercept (50 mg, once weekly for 12 weeks) vsplacebo in 39 patients with severe corticosteroid refractory asthmaResults◦ Decrease in Asthma Control Questionnaire (ACQ) scores were:
Etanercept; -1.11 (95% CI -1.56 to -0.75) and Placebo; -0.52 (95% CI -0.97 to -0.07), P = .037
◦ No significant differences in Asthma Related Quality of Life (AQLQ)Peak expiratory flow (PEF)Bronchial hyperresponsiveness (BHR)
Cytokine Inhibitors: Cytokine Inhibitors: EtanerceptEtanercept
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
49Send discussion questions to [email protected]
Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med. 2006;174(7):753-762.
Another TNF antagonistErin et al (2006) conducted a double-blind, placebo-controlled, parallel-group design study comparing infliximab (5 mg/kg iv at weeks 0, 2, and 6) with placebo in 38 patients with moderate asthma treated with ICS but symptomatic during a run-in phase At the end of the study, no significant difference in the primary end point was observed (morning PEF at end of study compared with end of run-in period) But the infliximab group had significantly fewer patients with exacerbations compared with placebo (29% vs72%)
Cytokine Inhibitors: Cytokine Inhibitors: InfliximabInfliximab
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
50Send discussion questions to [email protected]
Bateman ED, Izquierdo JL, Harnest U, et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol. 2006;96(5):679-686.
Phosphodiesterase type 4 (PDE4) is expressed in inflammatory cells involved in the pathogenesis of asthmaInhibition of PDE4 activity prevents the breakdown of cAMP, resulting in down-regulation of the inflammatory processes in cells involved in the pathogenesis of asthmaRoflumilast used in Europe for COPD; approved in March 2011 by FDA for severe COPD
PDE InhibitorsPDE Inhibitors
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
51Send discussion questions to [email protected]
Bousquet J, Aubier M, Sastre J, et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate (BDP) in the treatment of persistent asthma. Allergy. 2006;61(1):72-78.
Bousquet et al (2006) compared roflumilast (500 μgonce daily) with inhaled beclomethasonedipropionate (200 μg twice daily) in a double blind, double-dummy, randomized, noninferiority study involving patients with persistent asthma (N = 499)At the end of the 12-week study, both medications significantly improved FEV1 (roflumilast 12% increase; BDP, 14% increase) and forced vital capacity (roflumilast, 270 ml increase; BDP, 330 ml increase)
PDE InhibitorsPDE Inhibitors
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
52Send discussion questions to [email protected]
PDE InhibitorsPDE Inhibitors
Bousquet J, Aubier M, Sastre J, et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate (BDP) in the treatment of persistent asthma. Allergy. 2006;61(1):72-78.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
53Send discussion questions to [email protected]
Oligonucleotides can target RNA or proteins to alter cellular signalingAdvantages◦ High degree of specificity◦ Broad range of potential targets◦ Easy to modify drug properties ◦ Ability to screen efficiently for off-target effects◦ Relatively short development time◦ Relative ease of formulation for inhaled delivery◦ Relative ease of formulation of combination drugs◦ Relative stability of drug compound
Parry-Billings M, Ferrar N, Sequin R. Oligonucleotides: new therapeutic approaches for asthma and chronic obstructive pulmonary disease. Current Opin Invest Drugs. 2010;11(11):1276-1285.
OligonucleotidesOligonucleotides
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
54Send discussion questions to [email protected]
Drug Type Drug Target StatusAntisense ASM-8 (Pharmaxis) CCR3 receptor and β-
chain of IL-3, IL-5, and GM-CSF receptors
Phase II
siRNA Excellair (ZaBeCorPharmaceutical)
Syk kinase Phase II
Immuno-stimulatory
CYT-003 (CytosBiotechnology)
TLR9 Phase II
Immuno-stimulatory
QAX-935 (IderaPharmaceuticals)
TLR9 Phase I
OligonucleotidesOligonucleotides
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
55Send discussion questions to [email protected]
ASM-8 has 2 modified phosphorothioate antisense oligonucleotides that target CCR3 as well as the beta chain of IL-3, IL-5, and GM-CSFGauvreau et al (2008) performed a phase 2, crossover study in 17 patients with mild atopic asthma who were randomized to inhale 1500 μg TPI ASM8 or placebo by nebulizer, once daily for 4 daysAn allergen inhalation challenge on day 3Results:◦ Compared with placebo, TPI ASM8 inhibited sputum
eosinophil influx by 46% (P = .02) and blunted the increase in total cells (63%) after allergen challenge
Gauvreau GM, Boulet LP, Cockcroft DW, et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med. 2008;177(9):952-958.
OligonucleotidesOligonucleotides: ASM: ASM--8 (TPI8 (TPI--ASMASM--8)8)
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
56Send discussion questions to [email protected]
CYT003-QbG10 is an immunostimulatory sequence drug encapsulated in a virus-like particleA phase 2 trial has been completedData unavailable but a press release noted that patients stabilized on ICSs were given CYT003-QbG10 or placebo as their dose of ICS was gradually reducedResults:◦ At the end of the 12-week study, average asthma symptom
score increased 29% in patients given placebo and decreased 33% in patients given CYT003-QbG10 (P = .01)
Cytos Biotechnology: Placebo controlled phase II study shows CYT003-QbG10 is safe and efficacious for the treatment of allergic asthma. Press Release (May 2010). www.cytos.com.
OligonucleotidesOligonucleotides: CYT003: CYT003--ObG10ObG10
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
57Send discussion questions to [email protected]
Bronchial thermoplasty◦ Heat is applied to the bronchus by bronchoscopyCastro et al (2010) randomized 288 patients with uncontrolled severe asthma (on ICS and LABA) to receive bronchial thermoplasty or sham during 3 bronchoscopy procedures scheduled 3 weeks apart
Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181(2):116-124.
NonpharmacologicNonpharmacologic OptionsOptions
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
58Send discussion questions to [email protected]
NonpharmacologicNonpharmacologic OptionsOptions
Castro M. Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181(2):116-124.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
59Send discussion questions to [email protected]
NonpharmacologicNonpharmacologic OptionsOptions
Castro M. Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181(2):116-124.
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
60Send discussion questions to [email protected]
What is the current state of asthma care?
How can we improve asthma care?
What are the new therapeutic options for asthma care and how effective are they?
Emerging Therapeutic Options Emerging Therapeutic Options for Asthmafor Asthma
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
61Send discussion questions to [email protected]
Improvement in our understanding of asthma pathophysiology and the development of novel therapies have created new options for patients with asthma who are not responding well to traditional treatments
More clinical trials are needed, but the future is promising for patients with asthma, including those with hard-to-treat, persistent asthma
ConclusionsConclusions
© 2011 Pharmacy Times Office of Continuing Professional Education (CPE).
62
THANK YOU!
For any questions regarding this activity, contact: [email protected]
Emerging Therapeutic Options Emerging Therapeutic Options for Asthmafor Asthma